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Abstract
Background: Community-acquired necrotizing pneumonia caused by Panton-Valentine leukocidin (PVL)-secreting
Staphylococcus aureus is a highly lethal infection that mainly affects healthy children and young adults. Both
methicillin-sensitive S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA) may carry the PVL-phage, but the
majority of publications relate to community-associated methicillin-resistant S. aureus (CA-MRSA) or mixed patient
groups. This study focuses on necrotizing pneumonia due to methicillin-sensitive S. aureus strains, with the purpose
to determine factors associated with outcome.
Methods: We report a patient with PVL secreting MSSA necrotizing pneumonia and performed a systematic
review of similar case in the literature. We analyzed factors associated with outcome.
Results: A total of 32 patient descriptions were retained for analysis. Septic shock (p = 0.007), influenza-like
prodrome (p = 0.02), and the absence of a previous skin and soft-tissue infection (p = 0.024) were associated with
fatal outcome. In multivariate analysis, influenza-like prodrome (odds ratio (OR), 7.44; 95% confidence interval (CI),
1.24-44.76; p = 0.028) and absence of previous skin and soft-tissue infection (OR, 0.09; 95% CI, 0.01-0.86; p = 0.036)
remained significant predictors of death.
Conclusions: Influenza-like prodrome may be predictive of adverse outcome in PVL-secreting MSSA necrotizing
pneumonia. In contrast, previous skin and soft-tissue infection may be associated with improved prognosis.
Background
Staphylococcus aureus is estimated to cause 1-10% of
community acquired pneumonias (CAP) and 20-50% of
nosocomial pneumonias [1]. It is an important factor of
influenza-related morbidity and mortality and approxi-
mately half of the patients with S. aureus pneumonia
have underlying comorbidities and risk factors [2,3]. In
1999, Lina et al. found an association between necrotiz-
ing pneumonia and Panton-Valentine leukocidin (PVL)-
secreting S. aureus [4]. In 2002, Gillet et al. defined the
clinical features of PVL-associated necrotizing pneumo-
nia, followed in 2007 by the description of risk factors
associated with mortality [5,6]. PVL is thought to be a
key factor in the pathogenesis of necrotizing pneumonia.
It forms pores in the cell and mitochondrial membrane
of neutrophils and macrophages and thus provokes cell
lysis and apoptosis with subsequent liberation of inflam-
matory mediators [4,7]. Some authors contest the patho-
genic potential of PVL and suggest the presence of PVL-
genes to be a marker of other virulence determinants
[8,9].
The global distribution of PVL-carrying S. aureus var-
ies geographically. In North America, the most domi-
nant clone is ST8-USA300, which is responsible for the
majority of community-associated methicillin-resistant S.
aureus MRSA (CA-MRSA)-related infections [10,11].
European isolates are more commonly methicillin-sensi-
tive S. aureus (MSSA) [4,6]. Overall, the prevalence of
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wide study examining the proportion of CA-MRSA
among S. aureus CAP during the 2006-2007 influenza
seasons found a prevalence of 79%, in contrast to 12%
between 1986 and 2005 [3]. The Health Protection
Agency Staphylococcus Reference Unit (HPA-SRU) in
England recorded a steady increase of PVL-positive S.
aureus between 2005 and 2009, with a majority of
strains being methicillin-sensitive (61.5% versus 38.5% in
2010) [12]. Molecular profiles of methicillin-sensitive
and methicillin-resistant PVL-carrying S. aureus reveal
close genetic similarity and the former are thought to
constitute a reservoir for the latter [13].
Current knowledge about clinical features and mortal-
ity of PVL-positive S. aureus necrotizing pneumonia is
based on series and case reports. The typical clinical
picture is a previously healthy child or young adult with
an influenza-like prodrome, who rapidly develops septic
shock and respiratory failure, in the context of multilo-
bar consolidation, pleural effusion, and airway hemor-
rhage [5]. Influenza-like prodrome, leuko- and
thrombocytopenia, airway hemorrhage, and pleural effu-
sion are considered predictive of fatal outcome [6]. Pub-
lished mortality rates vary between 40% and 60%
[3,6,14,15]. One study compared outcome between
MSSA and MRSA strains, without finding a significant
difference [14].
We report a patient with PVL-secreting MSSA-necro-
tizing pneumonia, who had a classical clinical presenta-
tion and was successfully treated with antitoxin
antibiotics and intravenous immunoglobulin. He was
included in a review and analysis of clinical characteris-
tics of reported patients with a PLV-positive methicillin-
sensitive S. aureus necrotizing pneumonia, with the goal
to confirm outcome factors.
Methods
We searched for case reports and case series about
PLV-positive MSSA-community-acquired pneumonias
published before April 2010, using PubMed, with the
search terms “community-acquired pneumonia,”“ necro-
tizing pneumonia,” and “Panton-Valentin leukocidin.”
The reference sections of case reports, case series, and
relevant research and review articles were scanned for
missed case reports and case series. Case series, which
lacked individual clinical patient descriptions, were
excluded. Only articles in English, French, and German
were analyzed. The patient treated in our own institu-
tion was included in the analysis. The extracted clinical,
microbiological, and outcome data were converted into
variables and analyzed accordingly. For continuous vari-
ables, results are summarized as mean ± SD and catego-
rical variables are expressed in proportions. Fisher’s
exact test and Student’s t test were used for categorical
and continuous variables, respectively. Variables signifi-
cantly associated with outcome in the univariate analysis
were included in a multivariable model. For all tests, a
two-tailed P value < 0.05 was considered to denote sta-
tistical significance. Data analysis was performed with
SAS 9.2 (SAS Institute Inc.: Cary, NC, USA).
Case report
A 32-year-old, previously healthy, Caucasian male pre-
sented with severe sepsis and acute respiratory failure.
In the previous week, he noted an influenza-like illness.
On examination, chest auscultation revealed discrete
inspiratory crackles over the lower lung fields. The chest
radiograph showed bilateral dense alveolo-interstitial
infiltrates predominant in the middle and lower lobes
(Figure 1). The leukocyte count was 2.8 G/l, with a left
shift of 38%. CRP was 193 mg/l. Other laboratory para-
meters were in the normal range. Because of a penicillin
allergy, the patient was started on levofloxacin. Within
the first 24 hours, hypoxemia worsened (PaO2/FiO2 <
100 mmHg), profound septic shock developed, and the
leukocyte count dropped to 0.9 G/l. Sheets of gram-
positive cocci on sputum stain prompted the addition of
vancomycin. A sputum culture grew MSSA. The HIV
test was negative. Polymerase chain reaction (PCR) per-
formed on a throat swab was positive for influenza B
(880 cp/ml). The patient remained febrile and a CT
scan on the third day revealed extensive infiltrations
with cavitations suggestive of multiple abscesses. Sus-
pecting a PVL toxin-secreting strain, antibiotherapy was
switched to clindamycin (600 mg qid) and linezolid (600
mg bid) to downregulate the production of the toxin.
High-dose intravenous immunoglobulin (2 g/kg) was
added for 2 days. Within the following 48 hours, fever
decreased with marked improvement of the patient’s
clinical condition and inflammatory parameters. Further
characterization of the S. aureus strain confirmed PVL
production. Despite rapid initial improvement, the
patient required prolonged mechanical ventilation and
antibiotherapy because of abscess development and sev-
eral episodes of acute respiratory distress after proximal
bronchi obstruction with plugs of necrotic lung tissue
(Figure 2). The total duration of clindamycin and linezo-
lid treatment was 29 and 34 days, respectively. The
patient was successfully weaned after 31 days of
mechanical ventilation and transferred to the medical
ward after 38 days in the intensive care unit. He was
discharged from the hospital after 50 days. On follow-
up 1 year later, he showed residual dyspnea with heavy
exertion but was working again full-time.
Results
The literature search for MSSA PVL-positive CAP
resulted in 31 patient descriptions out of 25 publications
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opean patients, 14 of which were from France. Six publi-
cations originated in the United States, three in Asia,
and one in Australia. Cases occurred between 1998 and
2009. Most case reports lack detailed data on history,
clinical, and laboratory characteristics. Table 1 lists the
variables, which were reported often enough to be
included in the analysis. Although 93% of patients (26/
28) had multilobar pulmonary involvement and were
likely to have ARDS, this diagnosis was not used as a
Figure 1 Chest radiograph on admission showing bilateral dense infiltrates.
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Page 3 of 7Figure 2 Lung CT scan on day 12 of hospitalization showing abscess formations in the right middle lobe (arrows).
Table 1 Univariate analysis of risk factors associated with mortality in patients with PVL-secreting MSSA-necrotizing
CAP
Died
(N = 13)
Survived
(N = 19)
Univariate analysis
OR (95% CI)
P value
Demographics
Age (yr), mean ± SD 25.6 ± 15.5 23.7 ± 17.2 0.752
Male gender 6/13 (46%) 14/19 (74%) 0.31 (0.07-1.36) 0.15
Clinical characteristics
Influenza-like prodrome
a 9/12 (75%) 4/16 (25%) 9.00 (1.60-50.7) 0.02
Confirmed influenza coinfection 0/3 3/4 (75%) 0.06 (0.002-2.08) 0.143
SSTI on admission 1/13 (8%) 9/19 (47%) 0.09 (0.01-0.86) 0.024
T° < 36° or > 38° on admission 7/11 (63%) 9/11 (82%) 0.39 (0.05-2.77) 0.635
Multilobar involvement 12/12 14/16 (87%) 4.31 (0.19-98.6) 0.492
Lower airway hemorrhage
b 11/12 (92%) 9/16 (56%) 8.56 (0.88-83.1) 0.088
Septic shock 11/11 7/15 (47%) 26.0 (1.30-522) 0.007
Laboratory findings
Leukocytopenia 9/11 (82%) 8/17 (47%) 5.06 (0.83-30.8) 0.115
Thrombocytopenia 2/8 (25%) 6/6 0.03 (0.001-0.75) 0.01
Coagulopathy 9/9 6/8 (75%) 7.31 (0.30-178.7) 0.206
Positive blood cultures 5/13 (38%) 8/17 (47%) 0.56 (0.13-2.41) 0.484
Treatment
Mechanical ventilation 11/12 (92%) 10/14 (71%) 10.7 (0.52-223) 0.33
First-line antibiotics targeting toxin production
c 0/12 0/18 – 1
Intravenous IgG 1/13 (8%) 5/19 (26%) 0.26 (0.03-2.51) 0.361
aInfluenza-like syndrome > 48 h before admission. Symptoms include fever, shivering, chills, malaise, dry cough, loss of appetite, body aches, and nausea.
bHemoptysis and/or macroscopic blood on bronchoscopy/BAL.
cClindamycin, linezolid, or rifampicin,
PVL, Panton-Valentine leukocidin; MSSA, methicillin-sensitive Staphylococcus aureus; CAP, community-acquired pneumonia; SSTI, skin and soft-tissue infection.
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monary wedge pressures.
The average age was 24.5 (interquartile range, 14-38)
years, and 13 patients died (41%). With the exception of
one patient who died after 20 days, the median time
from admission to death was 20 hours. Univariate analy-
sis found that influenza-like prodrome (p =0 . 0 2 ) ,
absence of skin and soft tissue infection (SSTI) on
admission (p = 0.024), and septic shock (p = 0.007)
were associated with death (Table 1). The multivariable
model confirmed an association with fatal outcome for
influenza-like prodrome (OR, 7.44; 95% CI, 1.24-44.76; p
= 0.028) and absent SSTI (OR, 0.09; 95% CI, 0.01-0.86; p
= 0.036). Among patients with SSTI, there was a lower
rate of preceding influenza-like syndrome (p = 0.0008),
septic shock (p = 0.014), mechanical ventilation (p =
0.047), and lower mortality (p = 0.024). None of the
patients received an initial antibiotherapy targeting the
PVL toxin production.
Discussion
Community-acquired necrotizing pneumonia due to S.
aureus-secreting PLV toxin is a highly lethal infection,
affecting a young and healthy population group [5].
The hallmarks are an influenza-like prodrome, leuko-
penia, rapid progression to septic shock, and respira-
tory distress, with multilobar necrosis and haemoptysis
[5,6,14].
In this series, the mortality rate was 41%, which is
lower than most of previously published rates
[3,5,14,15]. On multivariable analysis, influenza-like pro-
drome predicted fatal outcome. The true proportion of
influenza infection is difficult to assess, because influ-
enza testing is not routinely performed and rapid test
sensitivity is only 50-70% [41]. Influenza impedes phago-
cytic killing and damages the trachea-bronchial epithe-
lium with subsequent impairment of secretion clearance
and facilitated bacterial adhesion [42-44]. The influenza-
like prodrome also may be caused by other respiratory
viruses or by S. aureus itself.
We found a significant reduction of mortality for
patients with skin and soft-tissue infection on admission.
This result is new in the context of PVL-associated S.
aureus necrotizing pneumonia, although one study men-
tioned a nonsignificant trend toward lower mortality for
patients with a history of furuncles [6] and a recent ret-
rospective study found a significant protective effect of a
history of PVL-associated infections [45]. Similar results
also have been published in studies on S. aureus car-
riers. Approximately 20-30% of healthy persons are per-
sistently colonized with S. aureus [44,46]. When
hospitalized, these carriers have an increased risk of
developing severe S. aureus infection caused by their
colonizing strain [47], but mortality of S. aureus
bacteremia is much lower in carriers than in noncarriers
[48]. The likely explanation for this protective effect is
the stimulation of an immune response, which lowers
the intensity of a subsequent invasive infection [49]. A
PVL vaccine has already been successfully tested on
mice models and may find a human application in the
near future [50].
Another issue raised by this study is the high rate of
inadequate initial antibiotic treatment regimens. None
of the 32 published cases received an antibiotic with an
antitoxin effect as part of their first-line treatment, and
all but three patients received beta-lactams. The use of
beta-lactams as first-line treatment is controversial,
because drug levels below the minimum inhibitory con-
centration may increase toxin release and stimulate
toxin production [37,38,51]. The former effect is due to
release of intracellular toxin secondary to cell wall lysis.
In vivo, low drug levels in target tissues are a conse-
quence of extensive tissue necrosis, leading to poor anti-
biotic diffusion and a sepsis-related increase of the
volume of distribution. However, the stimulatory effect
on toxin release is reversed when beta-lactams are given
in association with clindamycin, linezolid, or rifampicin
[52]. The high rate of inadequate initial antibiotic treat-
ment may be explained by the low prevalence of necro-
tizing S. aureus pneumonia, the low specificity of initial
clinical signs and symptoms, and the adherence to treat-
ment guidelines for community-acquired pneumonias.
However, even after overt clinical suspicion or microbio-
logical confirmation of PVL-secreting S. aureus,o n l y
36% (5/14) of second-line antibiotics were adequate. Not
surprisingly, the rate of adequacy was higher among
more recent case reports. Since 2007, the Infectious Dis-
eases Society of America (IDSA) recommends adding
vancomycin or linezolid in case of severe pneumonia
d u et oC A - M R S A[ 5 3 ] .I nt h eU n i t e dK i n g d o m ,t h e
Health Protection Agency (HPA) recommends a combi-
nation of clindamycin, linezolid, and rifampicin but
explicitly dissuades from the use of beta-lactams [54].
Based on the discussed in vitro findings for beta-lac-
tams, a recent recommendation by Gillet et al. suggests
a third-generation cephalosporin with vancomycin and
clindamycin or linezolid as first-line antibiotherapy. In
the case of MSSA, vancomycin can be replaced by oxa-
cillin [55].
Intravenous immunoglobulin may be an important
adjunct to antibiotherapy. As illustrated in the above
and in other case reports, it has been used successfully
on a sporadic basis [30,36,56]. It was studied in vitro
and was shown to neutralize PVL-induced pore forma-
tion and cytopathic effect [57]. The HPA recommends
intravenous immunoglobulin at a dose of 2 g/kg to be
repeated after 48 hours if there is persistence of septic
shock or failure to respond [54].
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reliance on a relatively small number of case reports.
Also, many variables, such as thrombocytopenia or kid-
ney function, were reported infrequently and thus could
not be included in the statistical analysis. We suspect
that only the most severe cases of CAP caused by PVL-
secreting MSSA are reported and that many cases are
not detected, making it difficult to describe the full
spectrum of clinical illness and to form meaningful con-
clusions based on the case reports. To improve our
knowledge of the epidemiology, diagnosis, and treat-
ment, there is a need to establish an international
database.
Conclusions
Necrotizing pneumonia due to PVL-secreting S. aureus
mandates prompt recognition and specific treatment to
prevent premature death in immunocompetent patients.
Early suspicion should be triggered by the presence of
influenza-like prodrome, leucopenia, rapid progression
to septic shock, respiratory distress with multilobar
necrosis, and hemoptysis. For PVL-secreting MSSA-
necrotizing pneumonia, influenza-like prodrome may be
associated with fatal outcome, whereas previous SSTI
may reduce mortality. Further studies based on a larger
patient number are necessary to confirm this finding.
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